Symptoms and General Pathology

All Conditions

Digestive System Diseases

Fistula

Pancreatic Fistula

Antineoplastic Agents

Gastrointestinal Agents

All Drugs and Chemicals

Octreotide

Antineoplastic Agents, Hormonal

After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days

After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days

Placebo

Dong Do You, MD, PhD

Kwang Yeol Paik, MD, Phd

This study aims to examine whether octreotide has an effect on inhibition of the exocrine secretion fo the pancreas, which might lower the rate of postoperative pancreatic fistula after pancreatoduodenectomy. Patients who will undergo pancreatoduodenectomy for periampullary tumors were enrolled. The patients were randomly assigned to intervention (use of octreotide) or placebo groups. Octreotide was injected subcutaneously every 8 hours for 7 days. Every patients will undergo pancreaticojejunostomy with external stent for remnant pancreas management. The pancreatic juice is drained through the external stent by negative pressure and amounted.

Primary endpoint was the amount of pancreatic juice for each postoperative day. Secondary endpoint was the rate of pancreatic fistula.

This study aims to examine whether octreotide has an effect on inhibition of the exocrine secretion fo the pancreas, which might lower the rate of postoperative pancreatic fistula after pancreatoduodenectomy. Patients who will undergo pancreatoduodenectomy for periampullary tumors were enrolled. The patients were randomly assigned to intervention (use of octreotide) or placebo groups. Octreotide of 100ug(1mL) was injected subcutaneously just before operation and every 8 hours for 7 days postoperatively. The placebo group was managed with normal saline (1mL) for same period. Every patients will undergo pancreaticojejunostomy with external stent for remnant pancreas management. The pancreatic juice is drained through the external stent by negative pressure (Barovac) and amounted.

Postoperative care of patients was same between groups such as pain control and supportive care. The amount of drained pancreatic juice via external stent was recorded everyday.

Primary endpoint was the amount of pancreatic juice for each postoperative day. Secondary endpoint was the rate of pancreatic fistula.

Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion

Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion and Pancreatic Fistula After Pancreatoduodenectomy

Saint Vincent's Hospital, Korea

Associated Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion	NCT02920567	Periampullary T...	Octreotide Placebo	19 Years - 80 Years	Saint Vincent's Hospital, Korea
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion	NCT02920567	Periampullary T...	Octreotide Placebo	19 Years - 80 Years	Saint Vincent's Hospital, Korea
Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion	NCT02920567	Periampullary T...	Octreotide Placebo	19 Years - 80 Years	Saint Vincent's Hospital, Korea

Spots Global Cancer Trial Database for periampullary tumors